이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunovia 관리

관리 기준 확인 1/4

Immunovia's CEO는 Jeff Borcherding, Apr2023 에 임명되었습니다 의 임기는 1.17 년입니다. 는 € 45.63K 가치에 해당하는 회사 주식의 0.77% 직접 소유합니다. 45.63K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 4.1 년입니다.

주요 정보

Jeff Borcherding

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.2yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO

Jeff Borcherding (51 yo)

1.2yrs

테뉴어

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeff Borcherding	Global Chief Executive Officer & President	1.2yrs	데이터 없음	0.77% SEK 49.6k
Karin Liwendahl	Chief Financial Officer	2.2yrs	데이터 없음	데이터 없음
Karl Stone	Chief Operating Officer	1.3yrs	데이터 없음	데이터 없음
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.3yrs	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 1YR 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Hongaard Andersen	Independent Chairman	4.1yrs	SEK 475.00k	데이터 없음
Hans Johansson	Independent Director	8.4yrs	SEK 280.00k	0.10% SEK 6.5k
Margaret Tempero	Member of Medical Advisory Board	8yrs	데이터 없음	데이터 없음
Diane Simeone	Member of Medical Advisory Board	7.9yrs	데이터 없음	데이터 없음
Michael Lofman	Independent Director	1.1yrs	SEK 175.00k	데이터 없음
Valerie Bogdan-Powers	Independent Director	less than a year	SEK 16.00k	데이터 없음
Stephen Pereira	Member of Medical Advisory Board	6.9yrs	데이터 없음	데이터 없음
Melissa Farina	Independent Director	less than a year	SEK 16.00k	데이터 없음
Martin Moller	Independent Director	3.1yrs	SEK 302.00k	데이터 없음

4.1yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 1YR 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Immunovia 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings released: kr7.43 loss per share (vs kr6.89 loss in FY 2021)

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings released: kr1.49 loss per share (vs kr2.18 loss in 2Q 2021)

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

First quarter 2022 earnings released: kr1.95 loss per share (vs kr1.04 loss in 1Q 2021)

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought €67k worth of stock

Independent Director recently bought €29k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령